87,261 XNAS Volume
XNAS 18 Mar, 2025 5:30 PM (EDT)
| Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|
| Emily Pimblett | SVP, Finance and CAO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Jan 2025 | 100,000 | 100,000 | - | - | Stock Option (Right to Buy) | |
| Brett Kaplan | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Jan 2025 | 500,000 | 500,000 | - | - | Stock Option (Right to Buy) | |
| Aoife M. Brennan | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Jan 2025 | 1,150,000 | 1,150,000 | - | - | Stock Option (Right to Buy) | |
| Stephen Thomas | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Jan 2025 | 50,188 | 50,187 | - | - | Restricted Stock Units | |
| Stephen Thomas | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Jan 2025 | 50,188 | 154,095 | - | - | Common Stock | |
| Pimblett Emily | CHIEF ACCOUNTING OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Dec 2024 | 5,000 | 12,564 | - | - | Common Stock | |
| Pimblett Emily | CHIEF ACCOUNTING OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Dec 2024 | 5,000 | 25,000 | - | - | Restricted Stock Units | |
| Emily Pimblett | CHIEF ACCOUNTING OFFICER | Sale of securities on an exchange or to another person at price $ 2.02 per share. | 18 Dec 2024 | 1,235 | 11,329 | - | 2.0 | 2,495 | Common Stock |
| Emily Pimblett | CHIEF ACCOUNTING OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Sep 2024 | 5,000 | 8,755 | - | - | Common Stock | |
| Emily Pimblett | CHIEF ACCOUNTING OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Sep 2024 | 5,000 | 30,000 | - | - | Restricted Stock Units | |
| Emily Pimblett | CHIEF ACCOUNTING OFFICER | Sale of securities on an exchange or to another person at price $ 8.11 per share. | 18 Sep 2024 | 9 | 7,564 | - | 8.1 | 73 | Common Stock |
| Emily Pimblett | CHIEF ACCOUNTING OFFICER | Sale of securities on an exchange or to another person at price $ 8.18 per share. | 18 Sep 2024 | 1,182 | 7,573 | - | 8.2 | 9,669 | Common Stock |
| Brett Kaplan | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Aug 2024 | 465,000 | 465,000 | - | - | Stock Option (Right to Buy) | |
| Brett Kaplan | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Aug 2024 | 77,500 | 77,500 | - | - | Restricted Stock Units | |
| Valerie Morisset | EVP, R&D AND CSO | Sale of securities on an exchange or to another person at price $ 7.09 per share. | 19 Jul 2024 | 10,201 | 150,322 | - | 7.1 | 72,325 | Common Stock |
| Valerie Morisset | EVP, R&D AND CSO | Sale of securities on an exchange or to another person at price $ 7.24 per share. | 19 Jul 2024 | 50,000 | 100,322 | - | 7.2 | 362,000 | Common Stock |
| Valerie Morisset | EVP, R&D AND CSO | Sale of securities on an exchange or to another person at price $ 7.98 per share. | 19 Jul 2024 | 30,000 | 31,317 | - | 8.0 | 239,400 | Common Stock |
| Valerie Morisset | EVP, R&D AND CSO | Sale of securities on an exchange or to another person at price $ 8.07 per share. | 19 Jul 2024 | 39,005 | 61,317 | - | 8.1 | 314,770 | Common Stock |
| Valerie Morisset | EVP, R&D AND CSO | Sale of securities on an exchange or to another person at price $ 6.91 per share. | 17 Jul 2024 | 3,207 | 199,099 | - | 6.9 | 22,160 | Common Stock |
| Valerie Morisset | EVP, R&D AND CSO | Sale of securities on an exchange or to another person at price $ 6.93 per share. | 17 Jul 2024 | 38,576 | 160,523 | - | 6.9 | 267,332 | Common Stock |
| Valerie Morisset | EVP, R&D AND CSO | Sale of securities on an exchange or to another person at price $ 7.13 per share. | 16 Jul 2024 | 50,000 | 202,306 | - | 7.1 | 356,500 | Common Stock |
| Valerie Morisset | EVP, R&D AND CSO | Sale of securities on an exchange or to another person at price $ 7.07 per share. | 12 Jul 2024 | 50,000 | 294,683 | - | 7.1 | 353,500 | Common Stock |
| Valerie Morisset | EVP, R&D AND CSO | Sale of securities on an exchange or to another person at price $ 7.01 per share. | 12 Jul 2024 | 42,377 | 252,306 | - | 7.0 | 297,063 | Common Stock |
| Valerie Morisset | EVP, R&D AND CSO | Sale of securities on an exchange or to another person at price $ 6.66 per share. | 09 Jul 2024 | 5,931 | 444,683 | - | 6.7 | 39,500 | Common Stock |
| Valerie Morisset | EVP, R&D AND CSO | Sale of securities on an exchange or to another person at price $ 6.83 per share. | 09 Jul 2024 | 50,000 | 394,683 | - | 6.8 | 341,500 | Common Stock |
| Valerie Morisset | EVP, R&D AND CSO | Sale of securities on an exchange or to another person at price $ 7.11 per share. | 09 Jul 2024 | 50,000 | 344,683 | - | 7.1 | 355,500 | Common Stock |
| Valerie Morisset | EVP, R&D AND CSO | Sale of securities on an exchange or to another person at price $ 7.06 per share. | 05 Jul 2024 | 12,342 | 450,614 | - | 7.1 | 87,135 | Common Stock |
| Valerie Morisset | EVP, R&D AND CSO | Sale of securities on an exchange or to another person at price $ 6.76 per share. | 01 Jul 2024 | 50,000 | 462,956 | - | 6.8 | 338,000 | Common Stock |
| Valerie Morisset | EVP, R&D AND CSO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Jul 2024 | 7,649 | 10,198 | - | - | Stock Option (Right to Buy) | |
| Valerie Morisset | EVP, R&D AND CSO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Jul 2024 | 7,649 | 512,956 | - | 0.0 | 2 | Common Stock |
| Aoife M. Brennan | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Jun 2024 | 275,000 | 275,000 | - | - | Restricted Stock Units | |
| Stephen Thomas | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Jun 2024 | 103,907 | 103,907 | - | - | Common Stock | |
| Stephen Thomas | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Jun 2024 | 100,375 | 100,375 | - | - | Restricted Stock Units | |
| Aoife M. Brennan | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Jun 2024 | 550,000 | 550,000 | - | - | Stock Option (Right to Buy) | |
| Simon Tate | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Jun 2024 | 10,000 | 10,000 | - | - | Stock Option (Right To Buy) | |
| Adam Rosenberg | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Jun 2024 | 10,000 | 10,000 | - | - | Stock Option (Right To Buy) | |
| Judith A. Dunn | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Jun 2024 | 10,000 | 10,000 | - | - | Stock Option (Right To Buy) | |
| Andrew Levin | Director, Executive Chairman | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Jun 2024 | 10,000 | 10,000 | - | - | Stock Option (Right To Buy) | |
| Liam Ratcliffe | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Jun 2024 | 10,000 | 10,000 | - | - | Stock Option (Right To Buy) | |
| Emily Pimblett | CHIEF ACCOUNTING OFFICER | Sale of securities on an exchange or to another person at price $ 7.21 per share. | 18 Jun 2024 | 1,245 | 3,755 | - | 7.2 | 8,982 | Common Stock |
| Emily Pimblett | CHIEF ACCOUNTING OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Jun 2024 | 5,000 | 5,000 | - | - | Common Stock | |
| Emily Pimblett | CHIEF ACCOUNTING OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Jun 2024 | 5,000 | 35,000 | - | - | Restricted Stock Units | |
| Valerie Morisset | EVP, R&D AND CSO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Apr 2024 | 17,847 | 505,307 | - | 0.0 | 4 | Common Stock |
| Valerie Morisset | EVP, R&D AND CSO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Apr 2024 | 17,847 | 28,046 | - | - | Stock Option (Right to Buy) | |
| Emily Pimblett | CHIEF ACCOUNTING OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Mar 2024 | 40,000 | 40,000 | - | - | Restricted Stock Units | |
| Valerie Morisset | EVP, R&D AND CSO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Sep 2023 | 5,431 | 472,163 | - | 0.0 | 11 | Common Stock |
| Valerie Morisset | EVP, R&D AND CSO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Sep 2023 | 15,297 | 45,893 | - | - | Stock Option (Right to Buy) | |
| Valerie Morisset | EVP, R&D AND CSO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Sep 2023 | 5,431 | 0 | - | - | Stock Option (Right to Buy) | |
| Valerie Morisset | EVP, R&D AND CSO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Sep 2023 | 15,297 | 487,460 | - | 0.0 | 3 | Common Stock |
| Liam Ratcliffe | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 May 2023 | 10,000 | 10,000 | - | - | Stock Option (Right To Buy) | |
| Andrew Levin | Director, Executive Chairman | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 May 2023 | 10,000 | 10,000 | - | - | Stock Option (Right To Buy) | |
| Judith A. Dunn | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 May 2023 | 10,000 | 10,000 | - | - | Stock Option (Right To Buy) | |
| Adam Rosenberg | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 May 2023 | 10,000 | 10,000 | - | - | Stock Option (Right To Buy) | |
| Simon Tate | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 May 2023 | 10,000 | 10,000 | - | - | Stock Option (Right To Buy) | |
| Valerie Morisset | EVP, R&D and CSO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2023 | 61,191 | 61,190 | - | - | Stock Option (Right to Buy) | |
| Valerie Morisset | EVP, R&D and CSO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2023 | 255,219 | 5,431 | - | - | Stock Option (Right to Buy) | |
| Valerie Morisset | EVP, R&D and CSO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2023 | 61,191 | 466,732 | - | 0.0 | 12 | Common Stock |
| Valerie Morisset | EVP, R&D and CSO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2023 | 255,219 | 405,541 | - | 0.0 | 510 | Common Stock |
| James B. Bucher | EVP and General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Oct 2022 | 95,000 | 95,000 | - | - | Stock Option (Right to Buy) | |
| Robert W. Azelby | Director, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Oct 2022 | 500,000 | 500,000 | - | - | Stock Option (Right to Buy) | |
| Erin M. Lavelle | COO & CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Oct 2022 | 170,000 | 170,000 | - | - | Stock Option (Right to Buy) | |
| Valerie Morisset | EVP, R&D and CSO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Oct 2022 | 170,000 | 170,000 | - | - | Stock Option (Right to Buy) | |
| Judith A. Dunn | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 May 2022 | 10,000 | 10,000 | - | - | Stock Option (Right To Buy) | |
| Leone D. Patterson | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 May 2022 | 10,000 | 10,000 | - | - | Stock Option (Right To Buy) | |
| Liam Ratcliffe | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 May 2022 | 10,000 | 10,000 | - | - | Stock Option (Right To Buy) | |
| Andrew Levin | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 May 2022 | 10,000 | 10,000 | - | - | Stock Option (Right to Buy) | |
| Adam Rosenberg | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 May 2022 | 10,000 | 10,000 | - | - | Stock Option (Right To Buy) | |
| Simon Tate | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 May 2022 | 10,000 | 10,000 | - | - | Stock Option (Right To Buy) | |
| James B. Bucher | EVP and General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Jan 2022 | 95,000 | 95,000 | - | - | Stock Option (Right to Buy) | |
| Robert W. Azelby | Director, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Jan 2022 | 500,000 | 500,000 | - | - | Stock Option (Right to Buy) | |
| Erin M. Lavelle | COO & CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Jan 2022 | 170,000 | 170,000 | - | - | Stock Option (Right to Buy) | |
| Valerie Morisset | EVP, R&D and CSO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Jan 2022 | 170,000 | 170,000 | - | - | Stock Option (Right to Buy) | |
| Liam Ratcliffe | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Aug 2021 | 20,000 | 20,000 | - | - | Stock Option (Right to Buy) | |
| Simon Tate | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Aug 2021 | 20,000 | 20,000 | - | - | Stock Option (Right to Buy) | |
| Adam Rosenberg | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Aug 2021 | 20,000 | 20,000 | - | - | Stock Option (Right to Buy) | |
| Andrew Levin | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Aug 2021 | 20,000 | 20,000 | - | - | Stock Option (Right to Buy) |